



UNITED STATES PATENT AND TRADEMARK OFFICE

CD
UNITED STATES DEPARTMENT OF COMMERCE
United States Patent and Trademark Office
Address: COMMISSIONER FOR PATENTS
P.O. Box 1450
Alexandria, Virginia 22313-1450
www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
09/890,562	10/09/2001	Toshikazu Yoshikawa	4296-145-US	4594
7590	07/28/2004		EXAMINER	
Mathews Collins Shepherd & Gould 100 Thanet Circle Suite 306 Princeton, NJ 08540			MAIER, LEIGH C	
			ART UNIT	PAPER NUMBER
			1623	

DATE MAILED: 07/28/2004

Please find below and/or attached an Office communication concerning this application or proceeding.

Office Action Summary	Application No.	Applicant(s)
	09/890,562	YOSHIKAWA ET AL.
	Examiner	Art Unit
	Leigh C. Maier	1623

-- The MAILING DATE of this communication appears on the cover sheet with the correspondence address --

Period for Reply

A SHORTENED STATUTORY PERIOD FOR REPLY IS SET TO EXPIRE 3 MONTH(S) FROM THE MAILING DATE OF THIS COMMUNICATION.

- Extensions of time may be available under the provisions of 37 CFR 1.136(a). In no event, however, may a reply be timely filed after SIX (6) MONTHS from the mailing date of this communication.
- If the period for reply specified above is less than thirty (30) days, a reply within the statutory minimum of thirty (30) days will be considered timely.
- If NO period for reply is specified above, the maximum statutory period will apply and will expire SIX (6) MONTHS from the mailing date of this communication.
- Failure to reply within the set or extended period for reply will, by statute, cause the application to become ABANDONED (35 U.S.C. § 133). Any reply received by the Office later than three months after the mailing date of this communication, even if timely filed, may reduce any earned patent term adjustment. See 37 CFR 1.704(b).

Status

1) Responsive to communication(s) filed on 28 May 2004.

2a) This action is **FINAL**. 2b) This action is non-final.

3) Since this application is in condition for allowance except for formal matters, prosecution as to the merits is closed in accordance with the practice under *Ex parte Quayle*, 1935 C.D. 11, 453 O.G. 213.

Disposition of Claims

4) Claim(s) 5-10 is/are pending in the application.

4a) Of the above claim(s) _____ is/are withdrawn from consideration.

5) Claim(s) _____ is/are allowed.

6) Claim(s) 5-10 is/are rejected.

7) Claim(s) _____ is/are objected to.

8) Claim(s) _____ are subject to restriction and/or election requirement.

Application Papers

9) The specification is objected to by the Examiner.

10) The drawing(s) filed on _____ is/are: a) accepted or b) objected to by the Examiner.

Applicant may not request that any objection to the drawing(s) be held in abeyance. See 37 CFR 1.85(a).

Replacement drawing sheet(s) including the correction is required if the drawing(s) is objected to. See 37 CFR 1.121(d).

11) The oath or declaration is objected to by the Examiner. Note the attached Office Action or form PTO-152.

Priority under 35 U.S.C. § 119

12) Acknowledgment is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f).

a) All b) Some * c) None of:

1. Certified copies of the priority documents have been received.
2. Certified copies of the priority documents have been received in Application No. _____.
3. Copies of the certified copies of the priority documents have been received in this National Stage application from the International Bureau (PCT Rule 17.2(a)).

* See the attached detailed Office action for a list of the certified copies not received.

Attachment(s)

1) Notice of References Cited (PTO-892)

2) Notice of Draftsperson's Patent Drawing Review (PTO-948)

3) Information Disclosure Statement(s) (PTO-1449 or PTO/SB/08)
Paper No(s)/Mail Date _____.

4) Interview Summary (PTO-413)
Paper No(s)/Mail Date. _____.

5) Notice of Informal Patent Application (PTO-152)

6) Other: _____.

DETAILED ACTION***Continued Examination Under 37 CFR 1.114***

A request for continued examination under 37 CFR 1.114, including the fee set forth in 37 CFR 1.17(e), was filed in this application after final rejection. Since this application is eligible for continued examination under 37 CFR 1.114, and the fee set forth in 37 CFR 1.17(e) has been timely paid, the finality of the previous Office action has been withdrawn pursuant to 37 CFR 1.114. Applicant's submission filed on May 28, 2004 has been entered.

The text of those sections of Title 35, U.S. Code not included in this action can be found in a prior Office action. Any objection or rejection not expressly repeated has been withdrawn.

Claim Rejections - 35 USC § 103

Claims 5-10 are rejected under 35 U.S.C. 103(a) as being unpatentable over MURASE et al (US 5,478,812) in view of CYNSHI et al (PNAS, 1998) as set forth in previous Office actions.

Applicant's arguments filed May 28, 2004 have been fully considered but they are not persuasive. Applicant states “[t]he references only suggest that anti-oxidants can be useful for treating arteriosclerosis, and MURASE only describes the *in vitro* anti-oxidant activity of the chromanol glycoside.” The examiner agrees, and this is exactly what is required to present a *prima facie* case that the art teaches the instant invention.

Applicant further notes that arteriosclerosis is believed to be mediated by many factors. That may be the case, but it is known in the art that anti-oxidants have utility in the treatment of arteriosclerosis, and Applicant has presented no evidence to suggest that some other additional *in vivo* process or activity is *required* for effective treatment.

Applicant further contends that the effectiveness of an agent cannot be definitively determined without a pharmacological test. Absolute predictability is not required in order of a *prima facie* case of obviousness to be established. All that is necessary is a reasonable expectation of success as supported by the art of record.


The declaration under 37 CFR 1.132 filed January 9, 2004 is insufficient to overcome the rejection the claims as set forth in the last Office action. The declaration discloses data regarding the effects of TMG on the expression of cell adhesion molecules. This finding, while being an important contribution to the scientific record, is not, in and of itself, germane to the instant rejection. First of all, there is no evidence that this is not an inherent property of other similar antioxidants, such as those taught by CYNSHI. Also, even if this property is not inherent, there is no evidence that the instant compounds have any greater efficacy in treating arteriosclerosis relative to other antioxidants having similar antioxidant activity. Evidence of the latter could be considered unexpected results.

Examiner's hours, phone & fax numbers

Any inquiry concerning this communication or earlier communications from the examiner should be directed to Leigh Maier whose telephone number is (571) 272-0656. The examiner can normally be reached on Tuesday, Wednesday, and Friday 7:00 to 3:30 (ET).

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Mr. James O. Wilson (571) 272-0661, may be contacted. The fax number for Group 1600, Art Unit 1623 is (703) 872-9306.

Visit the U.S. PTO's site on the World Wide Web at <http://www.uspto.gov>. This site contains lots of valuable information including the latest PTO fees, downloadable forms, basic search capabilities and much more.



Leigh C. Maier
Patent Examiner
July 23, 2004